More than 530 million people worldwide living with diabetes are at risk for developing diabetic retinal disease (DRD), the ...

The $66 million project is part of the company's obligation made to the state after it moved here to invest a total of $120 ...

Privately-held German drugmaker Boehringer Ingelheim and researchers from the Stanley Center for Psychiatric Research at the ...

The state-of-the-art research and development center in Georgia will help improve the health and wellbeing of animals ...

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

Boehringer Ingelheim has halted development of an obesity drug from Gubra that it originally pledged to advance back in 2017, ...

Spending the day facing the challenges of kidney patients helps workers at a CT pharmaceutical company understand disease and ...

Boehringer Ingelheim Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company ...

Abdulla also aims to further strengthen relationships with regional governments and key healthcare stakeholders to ensure ...

A while back, pharmaphorum web editor Nicole Raleigh spoke with Daniel Schwenk, senior principal clinical data manager at Boehringer Ingelheim, and Andrea Kloeble, Product Owner, Boehringer ...

More than 530 million people worldwide living with diabetes are at risk for developing diabetic retinal disease (DRD), the leading cause of blindness in working-age adults. 1·DRD is a growing epidemic ...